Pharmaceutical News

RSS

Researchers warn about taking psilocybin-containing ‘magic mushrooms’

In a survey of almost 2,000 people who said they had had a past negative experience when taking psilocybin-containing "magic mushrooms," Johns Hopkins researchers say that more than 10 percent believed their worst "bad trip" had put themselves or others in harm's way, and a substantial majority called their most distressing episode one of the top 10 biggest challenges of their lives.

30 Dec 2016

Mylan announces U.S. launch of generic Zovia Tablets

Mylan N.V., today announced the U.S. launch of Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP, 1 mg / 0.05 mg. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Zovia® 1/50E-28 Tablets (Watson).

30 Dec 2016

Legalization of recreational marijuana changes teens' use and perceptions of marijuana

Marijuana use significantly increased and its perceived harm decreased among eighth- and 10th-graders in Washington state following enactment of recreational marijuana laws, according to a UC Davis and Columbia University Mailman School of Public Health to be published online in JAMA Pediatrics.

30 Dec 2016

Psychiatric and behavioral conditions are important risk factors for long-term opioid use

A wide range of pre-existing psychiatric and behavioral conditions and the use of psychoactive drugs could be important risk factors leading to long-term use of opioid pain medications, reports a study in PAIN, the official publication of the International Association for the Study of Pain (IASP).

30 Dec 2016

Mylan announces U.S. launch of generic Concerta Tablets

Mylan N.V., today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta Tablets.

30 Dec 2016

Aromatase inhibitors show advantages over tamoxifen in early-stage breast cancer

The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether and what advantages drugs from the drug class of aromatase inhibitors offer compared with other breast cancer treatments or with each other.

30 Dec 2016

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" cholesterol, despite being treated with statins.

29 Dec 2016

Research reveals how microbial context during infectious disease can compromise antibiotic therapy

Bacteria that are susceptible to antibiotics can survive when enough resistant cells around them are expressing an antibiotic-deactivating factor.

28 Dec 2016

Combination of diabetes and hypertension drugs can effectively treat cancer

A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells.

27 Dec 2016

Potential drug could become first effective treatment option for Prader-Willi syndrome

Duke Health researchers have identified a drug-like small molecule that, in animal experiments, appears to be an effective treatment for a genetic disorder called Prader-Willi syndrome.

27 Dec 2016

Whitehead Institute researchers identify mechanism underlying cancer drug-resistance

The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs.

27 Dec 2016

Novel investigational drug may help restore cardiac function after heart failure

Cimaglermin, a new experimental drug, may help restore cardiac function after heart failure, according to a first-in-man study published today in JACC: Basic to Translational Science.

27 Dec 2016

Experimental drug improves survival, growth outcomes in mouse model of Prader-Willi syndrome

Drugs capable of activating silenced genes improve survival and growth outcomes in a mouse model of Prader-Willi syndrome, a rare and incurable childhood disease, according to a study funded by the National Institutes of Health.

27 Dec 2016

Saint Louis University geriatrician urges older patients to talk to doctors about too many pills

If you're 65 or older and taking more than four medications, resolve to talk to your doctor about doing a New Year's triage to make sure too many pills aren't making you sick, advises Milta Little, D.O., associate professor of geriatrics at Saint Louis University.

26 Dec 2016

CSHL researcher-inventor hails FDA approval of new SMA drug

Within a week of Christmas day, a drug called nusinersen will be in the hands of doctors across the nation, who will use it, most urgently, to treat young children with a severe and potentially fatal illness called spinal muscular atrophy (SMA).

26 Dec 2016

Ionis announces FDA approval of first SMA drug in the U.S for pediatric and adult patients

Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has approved SPINRAZATM (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

26 Dec 2016

Slayback Pharma launches Generic Zovirax Ointment 5% for herpes virus infections

Slayback Pharma LLC is pleased to announce the launch of Generic Zovirax Ointment (Acyclovir Ointment) 5%, by its out-licensee - Sandoz (Fougera). Slayback had developed the product and out-licensed the sales and marketing rights to Sandoz.

23 Dec 2016

MDA celebrates FDA approval of new spinal muscular atrophy drug

The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration's decision to grant approval for nusinersen (brand name Spinraza), the first disease-modifying drug to treat the most common genetic cause of death in infants.

23 Dec 2016

FDA approves first drug to treat children and adults with spinal muscular atrophy

The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

23 Dec 2016

Cycle Pharmaceuticals receives license for IP on PARP inhibitor drugs for treating vascular disease

Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to CYCLE Pharmaceuticals.

23 Dec 2016

Pharmaceutical News

Researchers warn about taking psilocybin-containing ‘magic mushrooms’

Mylan announces U.S. launch of generic Zovia Tablets

Legalization of recreational marijuana changes teens' use and perceptions of marijuana

Psychiatric and behavioral conditions are important risk factors for long-term opioid use

Mylan announces U.S. launch of generic Concerta Tablets

Aromatase inhibitors show advantages over tamoxifen in early-stage breast cancer

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

Research reveals how microbial context during infectious disease can compromise antibiotic therapy

Combination of diabetes and hypertension drugs can effectively treat cancer

Potential drug could become first effective treatment option for Prader-Willi syndrome

Whitehead Institute researchers identify mechanism underlying cancer drug-resistance

Novel investigational drug may help restore cardiac function after heart failure

Experimental drug improves survival, growth outcomes in mouse model of Prader-Willi syndrome

Saint Louis University geriatrician urges older patients to talk to doctors about too many pills

CSHL researcher-inventor hails FDA approval of new SMA drug

Ionis announces FDA approval of first SMA drug in the U.S for pediatric and adult patients

Slayback Pharma launches Generic Zovirax Ointment 5% for herpes virus infections

MDA celebrates FDA approval of new spinal muscular atrophy drug

FDA approves first drug to treat children and adults with spinal muscular atrophy

Cycle Pharmaceuticals receives license for IP on PARP inhibitor drugs for treating vascular disease

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News